ArticleEuropean journal of nuclear medicine and molecular imaging2023
SUV
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Quantitative PSMA PET Biomarkers for Predicting Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- Investigating the significance of SPECT/CT-SUV for monitoringBMC medical imaging · 2025Pooled it
- Efficacy and outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- Baseline PSMA-ligand PET/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy.Annals of nuclear medicine · 2026Article
- Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026Review
- [European journal of nuclear medicine and molecular imaging · 2026Article
- The Clinical Significance of Gallium-68 PSMA-11 PET-Derived SUVmax in the Management of Metastatic Hormone-Sensitive Prostate Cancer.The Prostate · 2026Article
- PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic value of whole-body tumor SUV dispersion on baseline PSMA PET prior to PSMA radioligand therapy.Annals of nuclear medicine · 2026Article
- ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer.European radiology · 2026Review
- Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617.European journal of nuclear medicine and molecular imaging · 2026Article
- FDG/PSMA discordance in [Frontiers in oncology · 2026Review
- Prognostic value of body composition out of PSMA-PET/CT in prostate cancer patients undergoing PSMA-therapy.European journal of nuclear medicine and molecular imaging · 2025Article
- Article
- PrognosticEuropean journal of nuclear medicine and molecular imaging · 2025Article
- PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who ReceivedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review.Frontiers in oncology · 2024Review
- Genes Selectively Expressed in Rat Organs.Current genomics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundQuantification of [
methodsWe retrospectively analyzed 103 patients with metastatic, castration-resistant PC who were treated with [
resultsA total of 48 patients died and median OS was 16 months. On univariable Cox regression, SUV
conclusionA lower SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.